Status In progress
Process STA
ID number 951

Provisional Schedule

Appraisal consultation: 1 01 September 2017 - 25 September 2017
Committee meeting: 2 04 October 2017
Expected publication 20 December 2017

Project Team

Project lead Thomas Feist

Email enquiries

Consultees

Companies sponsors AstraZeneca
Others Department of Health
  Welsh Government
Patient carer groups Breast Cancer Care
  Breast Cancer Now
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College pf Radiologists

Commentators

Comparator companies Pfizer
Evidence review group National Institute for Health Research Technology Assessment Programme (NETSCC)
  Southampton Health Technology Assessment (SHTAC)
General commentators All Wales Therapeutics and Toxiocology Centre
  British National Formulary
  Department of Health and Social Services and Public Safety, Northern Ireland (BHSSPSNI)
  Health Improvement Scotland
  Welsh Health Specialised Services
Relevant research groups Institute of Cancer Research
  National Cancer Research (NCRI)

Timeline

Key events during the development of the guidance:

Date Update
08 August 2017 Committee meeting: 1
15 March 2017 The appraisal of fulvestrant for untreated hormone-receptor positive metastatic breast cancer [ID951] has been rescheduled following an update on regulatory timings from the company. The first committee meeting will now take place on 08 August 2017.
13 December 2016 Invitation to participate
08 June 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance